Amgen lipid-lowering drug meets phase three endpoints

Evolocumab, Amgen’s human monoclonal antibody for the treatment of a genetic cause of high cholesterol, has performed well in a phase three trial.

Evolocumab, in combination with statins and other lipid-lowering therapies, met its primary endpoints in the trial in patients with heterozygous familial hypercholesterolemia – giving reductions in low-density lipoprotein cholesterol levels at ten and 12 weeks.

“Data from the RUTHERFORD-2 study suggest that evolocumab, when used as an add-on therapy to existing lipid-lowering medications, may offer a new treatment option for patients with heterozygous familial hypercholesterolemia.”

Sean Harper, executive vice-president of R&D, Amgen

 

pharmaphorum-youtube-page

Related news:

Amgen readies cholesterol drug after results from trial (Bloomberg).

Amgen’s cholesterol fighter succeeds in fifth late-stage study (Reuters).

Reference links:

Amgen announces positive top-line results from phase 3 RUTHERFORD-2 trial of evolocumab (AMG 145) in patients with heterozygous familial hypercholesterolemia (Amgen press release).

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.